EA201890968A1 - Комбинированная терапия для лечения злокачественных новообразований - Google Patents
Комбинированная терапия для лечения злокачественных новообразованийInfo
- Publication number
- EA201890968A1 EA201890968A1 EA201890968A EA201890968A EA201890968A1 EA 201890968 A1 EA201890968 A1 EA 201890968A1 EA 201890968 A EA201890968 A EA 201890968A EA 201890968 A EA201890968 A EA 201890968A EA 201890968 A1 EA201890968 A1 EA 201890968A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- norroformation
- malignant
- treatment
- combined therapy
- idh2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242256P | 2015-10-15 | 2015-10-15 | |
| US201562255194P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/057083 WO2017066599A1 (en) | 2015-10-15 | 2016-10-14 | Combination therapy for treating malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890968A1 true EA201890968A1 (ru) | 2018-09-28 |
Family
ID=57208385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890968A EA201890968A1 (ru) | 2015-10-15 | 2016-10-14 | Комбинированная терапия для лечения злокачественных новообразований |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10905692B2 (enExample) |
| EP (2) | EP4147692A1 (enExample) |
| JP (2) | JP2018534288A (enExample) |
| KR (2) | KR20180063125A (enExample) |
| CN (1) | CN108366980A (enExample) |
| AU (1) | AU2016340087C1 (enExample) |
| BR (1) | BR112018007304A2 (enExample) |
| CA (1) | CA3001599A1 (enExample) |
| CL (1) | CL2018000927A1 (enExample) |
| EA (1) | EA201890968A1 (enExample) |
| IL (2) | IL311873A (enExample) |
| MX (2) | MX394796B (enExample) |
| SG (1) | SG10201912886XA (enExample) |
| WO (1) | WO2017066599A1 (enExample) |
| ZA (1) | ZA201802088B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9694013B2 (en) | 2014-09-29 | 2017-07-04 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| BR112018007447B1 (pt) | 2015-10-15 | 2023-12-05 | Celgene Corporation | Uso de 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2- (trifluorometil) piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan2-ol e composição farmacêutica compreendendo o referido composto |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| JP2019529534A (ja) | 2016-09-07 | 2019-10-17 | セルジーン コーポレイション | 錠剤組成物 |
| US11229653B2 (en) | 2017-05-05 | 2022-01-25 | Celgene Corporation | Methods of treatment of myeloproliferative neoplasm |
| KR20200027548A (ko) * | 2017-07-09 | 2020-03-12 | 바이오사이트 리미티드 | 병용 암 요법 |
| US10980788B2 (en) * | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| JP2023503842A (ja) | 2019-11-14 | 2023-02-01 | セルジーン コーポレーション | がんを処置するための小児用製剤 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| DE60123384T2 (de) | 2000-02-04 | 2007-08-02 | DepoMed, Inc., Menlo Park | Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| ES2740424T3 (es) | 2009-03-13 | 2020-02-05 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| CA2793836C (en) * | 2009-10-21 | 2020-03-24 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| HUE038403T2 (hu) | 2012-01-06 | 2018-10-29 | Agios Pharmaceuticals Inc | Terápiásan alkalmazható vegyületek és alkalmazási módszereik |
| NZ715738A (en) | 2013-07-11 | 2021-06-25 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| AU2014295938B2 (en) | 2013-08-02 | 2018-07-19 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| US9694013B2 (en) | 2014-09-29 | 2017-07-04 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3253746A1 (en) | 2015-02-04 | 2017-12-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| JP6816106B2 (ja) | 2015-08-05 | 2021-01-20 | アジオス ファーマシューティカルズ， インコーポレイテッド | ６−ピリジル−１，３，５−トリアジン−２，４−ジオール及び６−ピリジル−１，３，５−トリアジン−２，４−ジアミンを調製する方法 |
| BR112018007447B1 (pt) | 2015-10-15 | 2023-12-05 | Celgene Corporation | Uso de 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2- (trifluorometil) piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan2-ol e composição farmacêutica compreendendo o referido composto |
| US10188656B2 (en) | 2015-12-04 | 2019-01-29 | Agios Pharmaceuticals, Inc. | Methods of treatment of malignancies |
| AU2016393869B2 (en) | 2016-02-26 | 2022-10-27 | Celgene Corporation | IDH2 inhibitors for the treatment of haematological maligancies and solid tumours |
-
2016
- 2016-10-14 IL IL311873A patent/IL311873A/en unknown
- 2016-10-14 US US15/768,480 patent/US10905692B2/en active Active
- 2016-10-14 SG SG10201912886XA patent/SG10201912886XA/en unknown
- 2016-10-14 BR BR112018007304A patent/BR112018007304A2/pt not_active Application Discontinuation
- 2016-10-14 KR KR1020187010260A patent/KR20180063125A/ko not_active Ceased
- 2016-10-14 KR KR1020257014978A patent/KR20250065944A/ko active Pending
- 2016-10-14 MX MX2018004595A patent/MX394796B/es unknown
- 2016-10-14 EP EP22196348.1A patent/EP4147692A1/en active Pending
- 2016-10-14 CA CA3001599A patent/CA3001599A1/en not_active Abandoned
- 2016-10-14 EP EP16787982.4A patent/EP3362057A1/en not_active Withdrawn
- 2016-10-14 WO PCT/US2016/057083 patent/WO2017066599A1/en not_active Ceased
- 2016-10-14 EA EA201890968A patent/EA201890968A1/ru unknown
- 2016-10-14 AU AU2016340087A patent/AU2016340087C1/en active Active
- 2016-10-14 CN CN201680060067.1A patent/CN108366980A/zh active Pending
- 2016-10-14 JP JP2018519487A patent/JP2018534288A/ja not_active Withdrawn
-
2018
- 2018-03-21 IL IL258269A patent/IL258269A/en unknown
- 2018-03-28 ZA ZA2018/02088A patent/ZA201802088B/en unknown
- 2018-04-11 CL CL2018000927A patent/CL2018000927A1/es unknown
- 2018-04-13 MX MX2022006701A patent/MX2022006701A/es unknown
-
2020
- 2020-12-24 US US17/133,994 patent/US20210386749A1/en not_active Abandoned
-
2021
- 2021-05-25 JP JP2021087311A patent/JP2021130682A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017066599A1 (en) | 2017-04-20 |
| US20210386749A1 (en) | 2021-12-16 |
| IL311873A (en) | 2024-06-01 |
| US20180311249A1 (en) | 2018-11-01 |
| MX2022006701A (es) | 2022-07-12 |
| CA3001599A1 (en) | 2017-04-20 |
| US10905692B2 (en) | 2021-02-02 |
| SG10201912886XA (en) | 2020-02-27 |
| BR112018007304A2 (pt) | 2018-10-23 |
| NZ740792A (en) | 2024-05-31 |
| AU2016340087A1 (en) | 2018-04-12 |
| KR20250065944A (ko) | 2025-05-13 |
| EP4147692A1 (en) | 2023-03-15 |
| CL2018000927A1 (es) | 2018-09-14 |
| MX394796B (es) | 2025-03-24 |
| AU2016340087C1 (en) | 2022-08-18 |
| AU2016340087B2 (en) | 2022-05-12 |
| JP2021130682A (ja) | 2021-09-09 |
| MX2018004595A (es) | 2019-07-04 |
| EP3362057A1 (en) | 2018-08-22 |
| ZA201802088B (en) | 2021-07-28 |
| JP2018534288A (ja) | 2018-11-22 |
| IL258269A (en) | 2018-05-31 |
| KR20180063125A (ko) | 2018-06-11 |
| CN108366980A (zh) | 2018-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890968A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| MX390531B (es) | Terapia de combinacion para tratar tumores malignos. | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| ZA201903327B (en) | Compositions and methods for the induction of cd8+ t¿cells | |
| MX2021007790A (es) | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| EP4085919A3 (en) | Compositions and methods to treat cancer | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| CL2015002807A1 (es) | Terapia de combinación | |
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
| MY190411A (en) | Improved uricase sequences and methods of treatment | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX2024014239A (es) | Composiciones que comprenden secuencias de consenso de tert y sus usos en el tratamiento del cancer | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| EA201890956A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| PH12022550743A1 (en) | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |